ALIGN Pharmaceuticals, Inc. Release: Xclair® Reported to Be Safe and Effective in Study Published in European Journal of Dermatology

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--ALIGN Pharmaceuticals, LLC, a wholly owned subsidiary of Cyclacel Pharmaceuticals, Inc., (NASDAQ: CYCC, CYCCP) announced results of a double-blinded, randomized, vehicle-controlled clinical study showing that Xclair® cream (formerly MAS065D) is safe and effective in the treatment and prevention of radiation dermatitis. These results were published in the May-June 2008 issue of the European Journal of Dermatology.